News Column

New Immunotherapy Findings from Gene Therapy Center Reported

June 2, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- New research on Biotechnology is the subject of a report. According to news reporting out of Beijing, People's Republic of China, by NewsRx editors, research stated, "Renal cell carcinoma (RCC) is a malignant disease that demonstrates resistance to standard chemotherapeutic agents. Yet Active immunization using genetically modified dendritic cells holds promise for the adjuvant treatment of malignancies to eradicate or control residual disease."

Our news journalists obtained a quote from the research from Gene Therapy Center, "Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8(+) T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with malignancies. This clinical trial was conducted to evaluate efficacy and safety of genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell (gmDCs-CIK) treatment of patients with RCC. 28 patients with advanced renal cancer were admitted to Affiliated Hospital of Academy of Military Medical Sciences from December 2010 to March 2012 and treated by gmDCs-CIK. Clinical efficacy and safety between pre- and post-treatment were compared. This analysis showed an objective response rate (ORR) of 39% and a disease control rate (DCR) of as 75%. There is no significant relationship between clinical efficacy and whether metastasis occurred or not (P > 0.05). There is no significant relationship between ORR and cycles of treatment (P > 0.05), but DCR was significantly related with cycles of treatment (P < 0.05). No clinically significant side effects were observed. There were no significant changes of T cell subsets including CD3(+), CD4(+), CD8(+), CD4(+) CD25(+) Treg cells except Th1 in peripheral blood between day 30 after immunotherapy and 1 day before immunotherapy in 11 patients."

According to the news editors, the research concluded: "DC-CIK is feasible and effective in treating advanced renal cancer and thus provides a new approach."

For more information on this research see: Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 2014;14():1-7. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)

Our news journalists report that additional information may be obtained by contacting D.H. Wang, Academy Military Med Sci, Cell & Gene Therapy Center, Beijing, People's Republic of China. Additional authors for this research include B. Zhang, H.Y. Gao, G.L. Ding, Q. Wu, J.C. Zhang, L. Liao and H. Chen (see also Biotechnology).

Keywords for this news article include: Asia, Antigen-Presenting Cells, Biotechnology, Kidney, Beijing, Genetics, Oncology, Cytokines, Immunology, Nephrology, Immunotherapy, Cancer Vaccines, Dendritic Cells, Immunomodulation, Clinical Research, People's Republic of China, Clinical Trials and Studies, Mononuclear Phagocyte System

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week